Cardlytics, Inc.

NasdaqGM:CDLX 株式レポート

時価総額:US$35.2m

Cardlytics 将来の成長

Future 基準チェック /06

Cardlyticsの収益は年間14.3%で減少すると予測されていますが、年間利益は年間56.2%で増加すると予想されています。EPS は年間60%で増加すると予想されています。

主要情報

56.2%

収益成長率

59.96%

EPS成長率

Media 収益成長35.7%
収益成長率-14.3%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日11 May 2026

今後の成長に関する最新情報

分析記事 23h

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...

Recent updates

分析記事 23h

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...
ナラティブ更新 May 01

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.
ナラティブ更新 Apr 17

CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential

Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.
ナラティブ更新 Apr 03

CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing

Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.
ナラティブ更新 Mar 20

CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential

Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.
ナラティブ更新 Mar 06

CDLX: Reset Expectations And CFO Return Will Support Future Rerating

Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.
分析記事 Jan 08

Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...
Seeking Alpha Oct 06

Cardlytics: Debt Overhang Casts Shadow On Upside

Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking Alpha
ナラティブ更新 Aug 08

Bank Partnerships And Data-Driven Marketing Will Shape Future Markets

The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.
分析記事 Jul 23

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%

Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...
分析記事 Jul 05

Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 May 29

Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
分析記事 Apr 07

Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
User avatar
新しいナラティブ Apr 03

US Neobank And Taiwan Office Will Unlock New Markets

Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.
分析記事 Mar 11

Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 Feb 21

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)

It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...
Seeking Alpha Feb 13

Cardlytics: Short-Term Headwinds Drive Long-Term Success

Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking Alpha
分析記事 Jan 10

At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?

Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...
Seeking Alpha Dec 07

Cardlytics Continues Revenue Contraction Amid Worsening Economics

Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking Alpha
分析記事 Nov 23

Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...
分析記事 Nov 05

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...
分析記事 Oct 15

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha Sep 17

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking Alpha
分析記事 Aug 09

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...
Seeking Alpha Jul 02

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking Alpha
分析記事 May 31

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...
Seeking Alpha Apr 17

The Power Of Cardlytics' Data Partnerships Including Bank of America

Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking Alpha
分析記事 Apr 10

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...
Seeking Alpha Feb 16

Cardlytics: Good Prospects But Macro Uncertain

Summary Cardlytics has access to 50% of card swipe data through its relationships with major US consumer banks. The company's acquisitions of Dosh and Bridg have strengthened and diversified its platform. The impact of macroeconomic factors on consumer spending and advertising budgets may constrain Cardlytics' growth in the short to medium term. Read the full article on Seeking Alpha
分析記事 Jan 18

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 29% in the last thirty...
分析記事 Jan 04

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 Oct 05

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

業績と収益の成長予測

NasdaqGM:CDLX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2027164-41-29-105
12/31/2026154-43-975
3/31/2026211-107-410N/A
12/31/2025233-103-69N/A
9/30/2025251-111-18-1N/A
6/30/2025266-183-20-1N/A
3/31/2025273-178-172N/A
12/31/2024278-189-28-9N/A
9/30/2024293-275-27-9N/A
6/30/2024305-153-26-9N/A
3/31/2024312-173-22-8N/A
12/31/2023309-135-130N/A
9/30/2023303-412-28-16N/A
6/30/2023296-382-44-32N/A
3/31/2023295-485-58-44N/A
12/31/2022299-465-67-54N/A
9/30/2022306-99-55-41N/A
6/30/2022298-150-51-37N/A
3/31/2022282-71-58-46N/A
12/31/2021267-129-51-39N/A
9/30/2021244-124-45-32N/A
6/30/2021225-94-40-27N/A
3/31/2021195-67-29-17N/A
12/31/2020187-55-18-8N/A
9/30/2020189-45-20-9N/A
6/30/2020199-38-27N/A
3/31/2020220-24-110N/A
12/31/2019210-17N/A11N/A
9/30/2019189-32N/A3N/A
6/30/2019167-33N/A-9N/A
3/31/2019154-39N/A-20N/A
12/31/2018151-53N/A-19N/A
9/30/2018142-46N/A-20N/A
6/30/2018139-41N/A-29N/A
3/31/2018136-33N/A-16N/A
12/31/2017130-25N/A-22N/A
9/30/2017128-28N/A-19N/A
6/30/2017127-51N/A-16N/A
3/31/2017120-77N/A-26N/A
12/31/2016113-77N/A-32N/A
12/31/201578-42N/A-29N/A

アナリストによる今後の成長予測

収入対貯蓄率: CDLX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CDLX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CDLX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CDLXの収益は今後 3 年間で減少すると予想されています (年間-14.3% )。

高い収益成長: CDLXの収益は今後 3 年間で減少すると予測されています (年間-14.3% )。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: CDLXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/11 10:55
終値2026/05/11 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cardlytics, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12

アナリスト機関
Omar DessoukyBofA Global Research
Jason KreyerCraig-Hallum Capital Group LLC
Robert CoolbrithEvercore ISI